Skip to main content
. 2018 Apr 17;47(4):1082–1097. doi: 10.1093/ije/dyy052

Table 5.

Infant blood concentrations for HCB pre- and postnatal exposure (3, 6, 12 and 24 months), estimated through pharmacokinetic modelling for lipophilic compounds (ng/g lipid)

Measured concentrations
Estimated HCB (ng/g lipid)
HCB (ng/g lipid)
Birth
3 months
6 months
12 months
24 months
Cohort Matrix n P25 Median P75 %<LOD P25 Median P75   P25 Median P75   P25 Median P75   P25 Median P75   P25 Median P75
INUENDO-Greenland MB 189 34.1 60.5 105.9 0% 30.4 56.3 94.8 55.0 102.0 170.0 57.4 113.8 191.5 62.0 111.1 232.8 54.8 97.9 203.9
INUENDO-Ukraine MB 161 77.8 100.9 145.0 0% 65.5 86.3 127.7 113.4 145.2 223.4 112.4 169.0 277.8 108.1 188.1 273.6 96.1 166.7 240.6
FLEHS I CB 248 10.2 22.3 36.5 24.20% 10.1 22.3 36.5 6.1 21.2 43.3 5.0 17.3 46.8 3.9 14.2 40.3 3.5 12.5 35.5
PELAGIE CB 188 5.4 11.1 17.3 21.2% 5.4 11.1 17.3 3.1 7.3 19.1 2.2 6.0 17.0 1.8 5.1 15.0 1.7 4.6 13.5
PCB cohort CB 452 41.2 75.6 133.1 3.6% 41.2 75.6 133.1 34.9 103.4 199.8 27.4 98.7 215.1 22.2 88.5 204.9 20.3 79.4 191.6
INMA-Menorca CB 251 234.1 310.0 457.5 11.6% 234.1 310.0 457.5 136.5 447.3 678.0 95.7 451.3 692.2 73.6 364.1 588.6 64.6 316.0 514.9
INMA-Valencia MB 347 40.5 74.6 118.2 4.3% 34.0 64.1 104.4 32.4 82.3 151.7 30.0 81.7 171.4 24.8 71.2 160.5 21.7 62.0 140.4
INMA-Sabadell MB 442 22.8 40.3 65.2 8.1% 19.5 35.3 58.3 28.2 53.0 86.3 27.5 54.8 93.2 22.4 49.4 89.5 19.6 43.6 78.4
INMA-Gipuzkoa MB 276 22.1 35.2 57.3 8.4% 18.3 30.8 49.3 27.8 45.2 84.1 23.3 52.8 89.8 19.3 50.5 94.4 16.7 44.7 83.3
HUMIS BM 1015 8.7 10.7 13.1 0% 9.5 11.8 14.6 16.3 20.5 25.3 20.9 27.5 34.5 23.0 31.7 40.4 23.4 34.2 46.0
DUISBURG MB 112 21.0 27.0 39.0 0% 18.1 23.9 34.8   28.9 39.0 58.0   34.2 48.6 76.6   34.4 65.2 94.0   30.4 61.0 91.7

MB: maternal blood; CB: cord blood; BM: breast milk; LOD: Limit of Detection; P25: 25th percentile; P75: 75th percentile.